875 related articles for article (PubMed ID: 35946879)
1. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
[TBL] [Abstract][Full Text] [Related]
2. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
5. Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.
Hoffmann P; Krisam J; Stremmel W; Gauss A
Dig Dis; 2019; 37(1):33-44. PubMed ID: 30134234
[TBL] [Abstract][Full Text] [Related]
6. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
Christensen B; Colman RJ; Micic D; Gibson PR; Goeppinger SR; Yarur A; Weber CR; Cohen RD; Rubin DT
Inflamm Bowel Dis; 2018 Mar; 24(4):849-860. PubMed ID: 29562271
[TBL] [Abstract][Full Text] [Related]
12. In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab.
Loly JP; Vieujean S; Reenaers C; Van Kemseke C; Seidel ScD L; Louis E; Somja J
Inflamm Bowel Dis; 2024 Feb; 30(2):240-246. PubMed ID: 37042951
[TBL] [Abstract][Full Text] [Related]
13. The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
Abraham BP; Fan C; Thurston T; Moskow J; Malaty HM
Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004241
[TBL] [Abstract][Full Text] [Related]
14. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
15. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
16. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study.
Cohen NA; Plevris N; Kopylov U; Grinman A; Ungar B; Yanai H; Leibovitzh H; Isakov NF; Hirsch A; Ritter E; Ron Y; Shitrit AB; Goldin E; Dotan I; Horin SB; Lees CW; Maharshak N
United European Gastroenterol J; 2020 Nov; 8(9):1076-1085. PubMed ID: 32807038
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.
Shelton E; Allegretti JR; Stevens B; Lucci M; Khalili H; Nguyen DD; Sauk J; Giallourakis C; Garber J; Hamilton MJ; Tomczak M; Makrauer F; Burakoff RB; Levine J; de Silva P; Friedman S; Ananthakrishnan A; Korzenik JR; Yajnik V
Inflamm Bowel Dis; 2015 Dec; 21(12):2879-85. PubMed ID: 26288002
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
[TBL] [Abstract][Full Text] [Related]
20. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Mocci G; Tursi A; Maconi G; Cataletti G; Mantia B; Serio M; Scarcelli A; Pagnini C; Graziani MG; Di Paolo MC; Pranzo G; Luppino I; Paese P; Elisei W; Monterubbianesi R; Faggiani R; Ferronato A; Perini B; Savarino E; Onidi FM; Binaghi L; Usai Satta P; Schiavoni E; Napolitano D; Scaldaferri F; Pugliese D; Pica R; Cocco A; Zippi M; Rodino S; Sebkova L; Rocco G; Sacchi C; Zampaletta C; Gaiani F; De Angelis G; Kayali S; Fanigliulo L; Lorenzetti R; Allegretta L; Scorza S; Cuomo A; Donnarumma L; Della Valle N; Sacco R; Forti G; Antonelli E; Bassotti G; Iannelli C; Luzza F; Aragona G; Perazzo P; Lauria A; Piergallini S; Colucci R; Bianco MA; Meucci C; Giorgetti G; Clemente V; Fiorella S; Penna A; De Medici A; Picchio M; Papa A
Expert Opin Biol Ther; 2023 Mar; 23(3):293-304. PubMed ID: 36843568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
